Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, realworld clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of tegoprazan- and rabeprazole-based triple therapy. Methods: We retrospectively reviewed data from patients who received first-line treatment for H. pylori infection using tegoprazan- or rabeprazole-based triple therapy for 2 weeks (50 mg tegoprazan or 20 mg rabeprazole+1,000 mg amoxicillin+500 mg clarithromycin twice daily). The primary endpoint was the eradication rate as determined by intention-to-treat analysis. Results: Of the 677 patients included in our study, 344 and 333 received tegoprazan-based and rabeprazole-based triple therapy, respectively. The eradication rate from intention-to-treat analysis was 76.7% (95% confidence interval [CI], 72.1% to 81.0%) for tegoprazan-based triple therapy and 75.4% (95% CI, 70.5% to 79.8%) for rabeprazole-based triple therapy. There was no significant difference in the eradication rates between the two groups (p>0.999). Per-protocol analysis also revealed no significant difference between the eradication rates of the two groups (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [79.0% to 87.4%], p>0.999). Furthermore, there was no significant difference in adverse event rates between the two groups (tegoprazan, 27.6%; rabeprazole, 25.8%; p=0.604). Conclusions: The eradication rate of tegoprazan-based triple therapy was similar to that of rabeprazole-based triple therapy. Further studies on the dose-escalation effect of tegoprazan for H. pylori eradication and the efficacy of tegoprazan in regimens other than conventional triple therapy are needed.
Abstract
Background/Aims: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, realworld clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of tegoprazan- and rabeprazole-based triple therapy. Methods: We retrospectively reviewed data from patients who received first-line treatment for H. pylori infection using tegoprazan- or rabeprazole-based triple therapy for 2 weeks (50 mg tegoprazan or 20 mg rabeprazole+1,000 mg amoxicillin+500 mg clarithromycin twice daily). The primary endpoint was the eradication rate as determined by intention-to-treat analysis. Results: Of the 677 patients included in our study, 344 and 333 received tegoprazan-based and rabeprazole-based triple therapy, respectively. The eradication rate from intention-to-treat analysis was 76.7% (95% confidence interval [CI], 72.1% to 81.0%) for tegoprazan-based triple therapy and 75.4% (95% CI, 70.5% to 79.8%) for rabeprazole-based triple therapy. There was no significant difference in the eradication rates between the two groups (p>0.999). Per-protocol analysis also revealed no significant difference between the eradication rates of the two groups (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [79.0% to 87.4%], p>0.999). Furthermore, there was no significant difference in adverse event rates between the two groups (tegoprazan, 27.6%; rabeprazole, 25.8%; p=0.604). Conclusions: The eradication rate of tegoprazan-based triple therapy was similar to that of rabeprazole-based triple therapy. Further studies on the dose-escalation effect of tegoprazan for H. pylori eradication and the efficacy of tegoprazan in regimens other than conventional triple therapy are needed.
참고문헌 (39)
- Hunt RH, "Helicobacter pylori in developing countries : World Gastroenterology Organisation global guideline", J Gastrointestin Liver Dis, 20, pp.299~304 (2011)
- McColl KE, "Clinical practice : Helicobacter pylori infection", N Engl J Med, 362, pp.1597~1604 (2010)
- de Martel C, "Global burden of cancers attributable to infections in 2008 : a review and synthetic analysis", Lancet Oncol, 13, pp.607~615 (2012)
- Guerra-Valle M, "Plant-based polyphenols: anti-Helicobacter pylori effect and improvement of gut microbiota", Antioxidants(Basel), 11, pp.109~ (2022)
- Sharndama HC, "Helicobacter pylori : an up-to-date overview on the virulence and pathogenesis mechanisms", Braz J Microbiol, 53, pp.33~50 (2022)
- Araújo GR, "Helicobacter pylori infection : how does age influence the inflammatory pattern?", World J Gastroenterol, 28, pp.402~411 (2022)
- Li WQ, "Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality : follow-up of a randomized intervention trial", BMJ, 366, pp.l5016~ (2019)
- Choi IJ, "Family history of gastric cancer and Helicobacter pylori treatment", N Engl J Med, 382, pp.427~436 (2020)
- Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer : systematic review and meta-analysis", Gut, 69, pp.2113~2121 (2020)
- Chiang TH, "Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality : a long-term cohort study on Matsu islands", Gut, 70, pp.243~250 (2021)
- Matsuo T, "Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese", Helicobacter, 16, pp.415~419 (2011)
- Hiroi S, "Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan : retrospective observational study and simulation study based on real-world data", BMJ Open, 7, pp.e015855~ (2017)
- Wagner S, "The role of omeprazole(40 mg)in the treatment of gastric Helicobacter pylori infection", Z Gastroenterol, 29, pp.595~598 (1991)
- Lee DH, "Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection", Yonsei Med J, 37, pp.270~277 (1996)
- Gisbert JP, "Evolution of Helicobacter pylori therapy from a meta-analytical perspective", Helicobacter, 12(Suppl 2), pp.50~58 (2007)
- Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
- Fock KM, "Second Asia-Pacific consensus guidelines for Helicobacter pylori infection", J Gastroenterol Hepatol, 24, pp.1587~1600 (2009)
- Sakurai Y, "Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects : a randomised open-label cross-over study", Aliment Pharmacol Ther, 42, pp.719~730 (2015)
- Jung YS, "Systematic review with metaanalysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication", Aliment Pharmacol Ther, 46, pp.106~114 (2017)
- Han S, "Randomised clinical trial : safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 50, pp.751~759 (2019)
- Lee KJ, "Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
- Kim SH, "Randomised clinical trial : comparison of tegoprazan and placebo in non-erosive reflux disease", Aliment Pharmacol Ther, 54, pp.402~411 (2021)
- Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 1, pp.87~97 (1969)
- Graham DY, "A report card to grade Helicobacter pylori therapy", Helicobacter, 12, pp.275~278 (2007)
- Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
- DeVault KR, "Insights into the future of gastric acid suppression", Nat Rev Gastroenterol Hepatol, 6, pp.524~532 (2009)
- Sugimoto M, "Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy", Helicobacter, 12, pp.317~323 (2007)
- Mizuno H, "Efficacy of vonoprazan for 48-week maintenance therapy of patients with healed reflux esophagitis", Digestion, 101, pp.411~421 (2020)
- 김지연, "Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth", Yonsei Medical Journal, 62(8), pp.708~716 (2021), 연세대학교의과대학[DOI]
- Choi Yoon Jin, "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial", Gut and Liver, 16(4), pp.535~546 (2022), 거트앤리버 소화기연관학회협의회[DOI]
- Horikawa C, "High risk of failing eradication of Helicobacter pylori in patients with diabetes : a meta-analysis", Diabetes Res Clin Pract, 106, pp.81~87 (2014)
- Gwilt PR, "The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans", Clin Pharmacokinet, 20, pp.477~490 (1991)
- Nam SJ, "Helicobacter pylori eradication in patients with type 2 diabetes mellitus : multicenter prospective observational study", SAGE Open Med, 7, pp.2050312119832093~ (2019)
- Groop LC, "Hyperglycaemia and absorption of sulphonylurea drugs", Lancet, 2, pp.129~130 (1989)
- Kong MF, "Gastric emptying in diabetes", Diabet Med, 13, pp.112~119 (1996)
- Marhoffer W, "Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes", Diabetes Care, 15, pp.256~260 (1992)
- Ishizaki T, "Review article : cytochrome P450 and the metabolism of proton pump inhibitors : emphasis on rabeprazole", Aliment Pharmacol Ther, 13(Suppl 3), pp.27~36 (1999)
- Yoon DY, "Prediction of drug-drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation", Pharmaceutics, 13, pp.1489~ (2021)